News
Keep on top of updates through our press releases.
Completed $200 million private placement post period Phase 3 COPD clinical trials planned to start later this year Pilot clinical study in patients hospitalized with COVID-19 planned to start in the third quarter Conference Call Today at 9:00 am EDT / 2:00 pm BST LONDON and RALEIGH, N.C., Aug.
LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial
LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three and six months ended June
LONDON and RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN
LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, provides further details regarding the transactions by persons
Inquires from press and journalists are welcome.